These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 28123123

  • 1. [Acute phase reaction following bisphosphonates.].
    Tsurukami H.
    Clin Calcium; 2017; 27(2):213-223. PubMed ID: 28123123
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion.
    Bertoldo F, Pancheri S, Zenari S, Boldini S, Giovanazzi B, Zanatta M, Valenti MT, Dalle Carbonare L, Lo Cascio V.
    J Bone Miner Res; 2010 Mar; 25(3):447-54. PubMed ID: 20200999
    [Abstract] [Full Text] [Related]

  • 7. Preventive Role of Vitamin D Supplementation for Acute Phase Reaction after Bisphosphonate Infusion in Paget's Disease.
    Merlotti D, Rendina D, Muscariello R, Picchioni T, Alessandri M, De Filippo G, Materozzi M, Bianciardi S, Franci MB, Lucani B, Cenci S, Strazzullo P, Nuti R, Gennari L.
    J Clin Endocrinol Metab; 2020 Mar 01; 105(3):. PubMed ID: 31634910
    [Abstract] [Full Text] [Related]

  • 8. The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass.
    Anastasilakis AD, Polyzos SA, Delaroudis S, Bisbinas I, Sakellariou GT, Gkiomisi A, Papadopoulou E, Gerou S, Makras P.
    Clin Endocrinol (Oxf); 2012 Dec 01; 77(6):816-22. PubMed ID: 22676573
    [Abstract] [Full Text] [Related]

  • 9. Addition of dexamethasone to manage acute phase responses following initial zoledronic acid infusion.
    Chen FP, Fu TS, Lin YC, Lin YJ.
    Osteoporos Int; 2021 Apr 01; 32(4):663-670. PubMed ID: 33113007
    [Abstract] [Full Text] [Related]

  • 10. No effect of rosuvastatin in the zoledronate-induced acute-phase response.
    Makras P, Anastasilakis AD, Polyzos SA, Bisbinas I, Sakellariou GT, Papapoulos SE.
    Calcif Tissue Int; 2011 May 01; 88(5):402-8. PubMed ID: 21305270
    [Abstract] [Full Text] [Related]

  • 11. Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration.
    Rossini M, Adami S, Viapiana O, Ortolani R, Vella A, Fracassi E, Gatti D.
    J Bone Miner Res; 2012 Jan 01; 27(1):227-30. PubMed ID: 21956654
    [Abstract] [Full Text] [Related]

  • 12. Recent advances in understanding the mechanism of action of bisphosphonates.
    Coxon FP, Thompson K, Rogers MJ.
    Curr Opin Pharmacol; 2006 Jun 01; 6(3):307-12. PubMed ID: 16650801
    [Abstract] [Full Text] [Related]

  • 13. Gamma-delta T lymphocytes and 25-hydroxy vitamin D levels as key factors in autoimmunity and inflammation: the case of zoledronic acid-induced acute phase reaction.
    De Santis M, Cavaciocchi F, Ceribelli A, Crotti C, Generali E, Fabbriciani G, Selmi C, Massarotti M.
    Lupus; 2015 Apr 01; 24(4-5):442-7. PubMed ID: 25801887
    [Abstract] [Full Text] [Related]

  • 14. Bisphosphonates: the first 40 years.
    Russell RG.
    Bone; 2011 Jul 01; 49(1):2-19. PubMed ID: 21555003
    [Abstract] [Full Text] [Related]

  • 15. Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass.
    Anastasilakis AD, Polyzos SA, Makras P, Sakellariou GT, Bisbinas I, Gkiomisi A, Delaroudis S, Gerou S, Ballaouri I, Oikonomou D, Papapoulos SE.
    Bone; 2012 May 01; 50(5):1130-4. PubMed ID: 22366634
    [Abstract] [Full Text] [Related]

  • 16. Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro.
    Thompson K, Rogers MJ.
    J Bone Miner Res; 2004 Feb 01; 19(2):278-88. PubMed ID: 14969398
    [Abstract] [Full Text] [Related]

  • 17. Long-term effects of amino-bisphosphonates on circulating γδ T cells.
    Rossini M, Adami S, Viapiana O, Fracassi E, Ortolani R, Vella A, Zanotti R, Tripi G, Idolazzi L, Gatti D.
    Calcif Tissue Int; 2012 Dec 01; 91(6):395-9. PubMed ID: 23052225
    [Abstract] [Full Text] [Related]

  • 18. Drug insight: Bisphosphonates for postmenopausal osteoporosis.
    Chapurlat RD, Delmas PD.
    Nat Clin Pract Endocrinol Metab; 2006 Apr 01; 2(4):211-9; quiz following 238. PubMed ID: 16932286
    [Abstract] [Full Text] [Related]

  • 19. A Strategy against the Osteonecrosis of the Jaw Associated with Nitrogen-Containing Bisphosphonates (N-BPs): Attempts to Replace N-BPs with the Non-N-BP Etidronate.
    Oizumi T, Yamaguchi K, Sato K, Takahashi M, Yoshimura G, Otsuru H, Tsuchiya M, Hagiwara Y, Itoi E, Sugawara S, Takahashi T, Endo Y.
    Biol Pharm Bull; 2016 Apr 01; 39(9):1549-54. PubMed ID: 27582334
    [Abstract] [Full Text] [Related]

  • 20. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
    Pyon EY.
    Clin Ther; 2006 Apr 01; 28(4):475-90. PubMed ID: 16750461
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.